Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET
Rhea-AI Summary
BioArctic AB (Nasdaq Stockholm: BIOA B) has announced it will release its Q1 2025 financial report on Wednesday, May 21, 2025, at 08:00 CET. Following the report's publication, the company will host an audiocast with teleconference in English at 09:30 CET.
CEO Gunilla Osswald and CFO Anders Martin-Löf will present the quarterly results and conduct a Q&A session. Participants can join via webcast or teleconference, with options for submitting questions either in writing through the webcast or verbally via the teleconference. The presentation will later be available on-demand through BioArctic's corporate website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, BIOA declined 1.97%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on May 21, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present and comment on the first quarter report, followed by a Q&A-session.
If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.
Webcast: https://bioarctic.events.inderes.com/q1-report-2025/register
If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/bioarctic/q1-report-2025/dial-in
The webcast will also be available on demand on BioArctic's corporate website https://www.bioarctic.com/en/investors/financial-reports-and-presentations/ after the presentation.
---
For more information, please contact:
Anders Martin-Löf, CFO
Phone: +46 70 683 79 77
E-mail: anders.martin-lof@bioarctic.com
This information was submitted for publication at 08:30 a.m. CET on May 13, 2025.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Invitation to presentation of BioArctic’s first quarter report for January - March 2025 |
View original content:https://www.prnewswire.com/news-releases/invitation-to-presentation-of-bioarctics-first-quarter-report-for-january---march-2025-on-may-21-at-9-30-am-cet-302453502.html
SOURCE BioArctic
FAQ
When will BioArctic (BIOA) release its Q1 2025 earnings report?
How can I participate in BioArctic's Q1 2025 earnings call?
Who will present BioArctic's Q1 2025 earnings results?
Where can I find BioArctic's Q1 2025 earnings presentation after the event?
